|
Monday, 08/02/2010
|
Development of Imaging Biomarkers for Clinical Trials: Applications in Glioblastoma Multiforme
Hyun (Grace) Kim, University of California, Los Angeles; Jing Huo, University of California, Los Angeles; Matt Brown, University of California, Los Angeles; Jonathan Goldin, University of California, Los Angeles
|
Development of Imaging Biomarkers for Clinical Trials: Applications in Rheumatoid Arthritis
Grace S. Park, Amgen Inc.
|
Semiparametric Transformation Models for Multiple Biomarkers in ROC Analysis
Eunhee Kim, Brown University; Donglin Zeng, The University of North Carolina at Chapel Hill
9:35 AM
|
Landmark Prediction of Survival
Layla Parast, Harvard University; Tianxi Cai, Harvard School of Public Health
10:35 AM
|
Statistics in Biopharmaceutical Research: Application of Biomarkers in Drug Development
Aloka Chakravarty, FDA; Mark Rothmann, FDA; Rajeshwari Sridhara , FDA
2:05 PM
|
Optimal Weight in Estimating the Receiver Operating Characteristic Curve Area Using Longitudinal Data
Yougui Wu, University of South Florida
2:05 PM
|
Detecting a Cutoff Point for Predictive Biomarkers in Clinical Trials Using Contrast Tests
Jianliang Zhang, MedImmune
2:20 PM
|
Using Logistic Model with Measurement Errors in Covariates to Assess Baseline Biomarkers Association with Treatment Response
Dion Chen, Centocor R&D, Inc.; Jiandong Lu, Johnson & Johnson
2:35 PM
|
Overcoming the Winner's Curse to Identify Biomarkers with Clinical Relevance in Drug Development
Lei Shen, Eli Lilly and Company; Haoda Fu, Eli Lilly and Company
3:20 PM
|
Estimating Incremental Value in Marker Combinations Using a Two-Stage Study Design
Aasthaa Bansal, University of Washington; Margaret Sullivan Pepe, Fred Hutchinson Cancer Research Center
3:35 PM
|
|
Tuesday, 08/03/2010
|
Can Spread of Data Be Used for Discrimination?
Borko D. Jovanovic, Northwestern University; Angela Fought, Northwestern University; Mary Kwasny, Northwestern University
|
Application of Intersection-Union Tests for Identifying Metabolite Biomarkers for Diagnosis and Prognosis
Kyoungmi Kim, University of California, Davis; Stanislav O. Zakharkin, Cadbury North America
|
Statistical Analysis Strategies for Shotgun Proteomics Data
Ming Li, Vanderbilt University School of Medicine
8:35 AM
|
A Bayesian Adaptive Design with Biomarkers for Targeted Therapies
Jens C. Eickhoff, Colorado State University; KyungMann Kim, University of Wisconsin-Madison; Jill M. Kolesar, University of Wisconsin-Madison; Jason R. Gee, Lahey Clinic Medical Center
10:35 AM
|
|
Thursday, 08/05/2010
|
Coherent Analysis of Longitudinal Changes in Biomarkers in the Presence of Attrition Due to Competing Risks
Tom Greene, The University of Utah
8:35 AM
|
Biomarkers in Clinical Trials in the Development of Biologics and Risk Assessment
Samir Lababidi, FDA
8:50 AM
|
A Review of Time-Dependent ROC Curve for Evaluating the Prognosis Capacity of Biomarkers and Semiparametric Regression Methods
Nan Hu, The University of Utah; Xiao-Hua Zhou, University of Washington
8:55 AM
|
Using Cardiovascular Disease Risk Functions in Public Health and Clinical Trial: The Framingham Study Experience
Ralph B. D'Agostino, Sr., Boston University
9:25 AM
|
Comparing Biomarkers as Principal Surrogate Endpoints
Ying Huang, Columbia University
11:15 AM
|
Parsimonious Models for Classifying Proteomic MS Data
Chris Fraley, Insilicos LLC; Bryan Prazen, Insilicos LLC; Mark Seligman, Insilicos LLC
11:20 AM
|
|